Global Meningococcal Vaccines Market, By Type (Bivalent, Quadrivalent), Age Group (Infants, Children, Adults), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Meningococcal Vaccines Market Analysis and Size
According to the Centers for Disease Control and Prevention (CDC) records, about 1.2 million cases of bacterial meningitis are estimated to occur globally each year. Bacterial meningitis can occur at any age. Whereas infants are at a larger risk of developing bacterial meningitis. Numerous campaigns and awareness programs are being organized by several government & non-government organizations.
Data Bridge Market Research analyses a growth rate in the meningococcal vaccines market in the forecast period 2023-2030. The expected CAGR of the meningococcal vaccines market tends to be around 6.7% in the mentioned forecast period. The market was valued at USD 3.07 million in 2022 and would grow to USD 5.16 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Meningococcal Vaccines Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Bivalent, Quadrivalent), Age Group (Infants, Children, Adults), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Limited (India), Sanofi S.A. (France), Merck & Co., Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (U.S.), Pfizer Inc. (U.S.), Serum Institute of India Pvt. Ltd (India), Incepta Pharmaceuticals Ltd. (India), Walvax Biotechnology Co., Ltd (China), Bio-Manguinhos (Brazil)
|
|
Market Opportunities
|
|
Market Definition
Meningococcal vaccine is typically zed as a vaccine used to prevent infection caused by Neisseria meningtidis. This vaccine is given either in the form of injection into the muscle and also under the skin. These vaccines are based on polysaccharide-based, glycoconjugate, protein-based and combined conjugate vaccines, which usually target the pathogen's serogroups. The meningococcal vaccine helps to decline the global incidence of meningococcal meningitis diseases.
Global Meningococcal Vaccines Market Dynamics
Drivers
- Rise In The Incidence Of Meningitis
A rise in the occurrence of meningitis is anticipated to increase the demand for meningitis vaccines, therefore pushing the growth of the meningococcal vaccines market. For instance, as per the data published by Elsevier Inc., the Netherlands-based academic publishing company, in April 2021, more than 2.5 million cases and 236,000 deaths because of meningitis were reported in 2019 worldwide.
- Increasing Awareness Programs About The Disease
Numerous campaigns and awareness programs are being organized by government & non-government organizations, such as the Meningitis Research Foundation of Canada, Meningitis B Action Project, National Meningitis Association (NMA), and others. These organizations help in promoting constant research and new approaches that are involved in disease prevention. Therefore, these factors are expected to fuel the market growth in the coming years.
Opportunities
- Growing R&D Activities
The existence of several vaccines and research activities of phase III vaccines in the pipeline which are projected to be commercialized during the forecast period and is anticipated to fuel the market growth. For instance, in June 2020, Pfizer, Inc. initiated phase III clinical trials of PF-06886992, which is a pentavalent meningococcal vaccine candidate (MenABCWY) to evaluate & compare the safety, immunogenicity, and tolerability with licensed meningococcal vaccines in adolescents and young adults. Furthermore, Menactra, a conjugate vaccine manufactured by Serum Institute of India Pvt. Ltd. is currently in phase III clinical trial. Thus, all these trials are boosting the growth of the market.
- Increasing Initiatives by Government Organizations
Growing initiatives by governments of countries and other regulatory authorities are expected to boost the growth of the market during the forecast period. For instance, in September 2021, WHO and its partners launched the first-ever global strategy, Global roadmap to defeat meningitis by 2030, to fight for meningitis. The main aim is to eliminate epidemics of bacterial meningitis and decrease deaths by 70% and reduce the number of cases by 2030
Restraints/Challenges
- High costs will derail the market growth
The huge expenditure associated with these agents impedes the market growth. For instance, in 2018, The Johns Hopkins University researchers assessed that requiring all college students to be vaccinated against meningitis B would not be that much cost-effective. Researchers peformed a survey and found that the universal immunization against serogroup B of meningococcal disease, or meningitis B, for college-aged students would only be beneficial if the vaccine costs less than US$ 65. The average price for it is US$ 324.
This meningococcal vaccines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the meningococcal vaccines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Meningococcal Vaccines Market
The COVID-19 pandemic had a negative impact on the market, due to a decrease in vaccination rates for meningitis. For instance, as per the article published by Elsevier B.V., in April 2022, the number of meningococcal C conjugate vaccine doses administered from March 2019 to December 2020 was analyzed in Brazil. There were total 14,832,054 meningococcal C conjugate vaccine doses administered; 66.30% of them from March 2019 to February 2020, and 33.70%, from March 2020 to December 2020. Thus, the COVID-19 pandemic had a negative economic impact on the global meningitis vaccines market because of the decreased vaccination rates.
Recent Development
- In April 2020, Sanofi received U.S. FDA approval for MenQuadfi. MenQuadfi is a quadrivalent meningococcal (Groups A, C, Y, W) conjugate vaccine for the prevention of invasive meningococcal disease in people aged 2 years & older.
Global Meningococcal Vaccines Market Scope
The meningococcal vaccines market is segmented on the basis of type, age group, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Bivalent
- Quadrivalent
Age Group
- Infants
- Children
- Adults
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Meningococcal Vaccines Market Regional Analysis/Insights
The meningococcal vaccines market is analyzed and market size insights and trends are provided by type, age group, distribution channel and end-user as referenced above.
The major countries covered in the meningococcal vaccines market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing positive growth for the meningococcal vaccines market throughout the forecasted period due to the presence of key manufacturers of the product is high and, increasing research and development activities, healthcare expenditure .
North America dominates the market due to increased new research and developments on meningococcal vaccines market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Meningococcal Vaccines Market Share Analysis
The meningococcal vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to meningococcal vaccines market.
Key players operating in the meningococcal vaccines market include:
- Johnson & Johnson Private Limited (U.S.)
- Mylan N.V. (U.S.)
- Sun Pharmaceutical Industries Limited (India)
- Sanofi S.A.(France)
- Merck & Co., Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AbbVie Inc. (U.S.)
- Fresenius Kabi AG (Germany)
- Amneal Pharmaceuticals LLC. (U.S.)
- Pfizer Inc. (U.S.)
- Serum Institute of India Pvt. Ltd (India)
- Incepta Pharmaceuticals Ltd. (India)
- Walvax Biotechnology Co., Ltd (China)
- Bio-Manguinhos (Brazil)
SKU-